VIDION® ANV® Therapy System -- The first medical device to utilise
epimacular brachytherapy for the treatment of neovascular AMD
VIDION® is a one-time outpatient procedure
VIDION® delivers targeted radiation without causing collateral damage
In preliminary clinical trials (n=34), utilising epimacular brachytherapy:
►91% of patients maintained their visual acuity at month 12
►Mean visual acuity improved by 8.9 letters
►38% of patients improved their vision by 3 or more lines
►73% of patients did not require any additional anti-VEGF treatments
